In a capital constrained and AI accelerated environment, value creation in health innovation is being redefined. Execution, consolidation, and platform thinking are replacing hype driven growth, with funding strategies prioritising capital efficiency, sustainable business models, and long term impact. Execution risk, integration complexity, and post deal operating readiness are now central to value creation, as M&A and exits are increasingly evaluated on post integration impact, scaling capability, and sustained outcomes—not financial metrics alone.